These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 30499777)
1. New Daily Persistent Headache and OnabotulinumtoxinA Therapy. Ali A; Kriegler J; Tepper S; Vij B Clin Neuropharmacol; 2019; 42(1):1-3. PubMed ID: 30499777 [TBL] [Abstract][Full Text] [Related]
2. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF; Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038 [TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic subforms of new daily-persistent headache. Robbins MS; Grosberg BM; Napchan U; Crystal SC; Lipton RB Neurology; 2010 Apr; 74(17):1358-64. PubMed ID: 20421580 [TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA in pediatric chronic daily headache. Kabbouche M; O'Brien H; Hershey AD Curr Neurol Neurosci Rep; 2012 Apr; 12(2):114-7. PubMed ID: 22274570 [TBL] [Abstract][Full Text] [Related]
5. Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine. Maasumi K; Thompson NR; Kriegler JS; Tepper SJ Headache; 2015 Oct; 55(9):1218-24. PubMed ID: 26381856 [TBL] [Abstract][Full Text] [Related]
6. Challenges in the management of new daily persistent headache at a tertiary headache center-A retrospective real-world evidence study. Linnet T; Hussein M; Schytz HW; Bendtsen L; Amin FM Headache; 2024 May; 64(5):509-515. PubMed ID: 38646979 [TBL] [Abstract][Full Text] [Related]
7. Triggering Events and New Daily Persistent Headache: Age and Gender Differences and Insights on Pathogenesis-A Clinic-Based Study. Rozen TD Headache; 2016 Jan; 56(1):164-73. PubMed ID: 26474179 [TBL] [Abstract][Full Text] [Related]
8. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. Matharu M; Halker R; Pozo-Rosich P; DeGryse R; Manack Adams A; Aurora SK J Headache Pain; 2017 Dec; 18(1):78. PubMed ID: 28766236 [TBL] [Abstract][Full Text] [Related]
10. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197 [TBL] [Abstract][Full Text] [Related]
11. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Cady RK; Schreiber CP; Porter JA; Blumenfeld AM; Farmer KU Headache; 2011 Jan; 51(1):21-32. PubMed ID: 21070228 [TBL] [Abstract][Full Text] [Related]
12. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235 [TBL] [Abstract][Full Text] [Related]
13. New daily persistent headache: a systematic review on an enigmatic disorder. Yamani N; Olesen J J Headache Pain; 2019 Jul; 20(1):80. PubMed ID: 31307396 [TBL] [Abstract][Full Text] [Related]